Shionogi & Co., Ltd. (SGIOY) Stock Price, News & Analysis

Company Overview

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug. It also develops S-872600 an influenza nasal vaccine; S-875670 anCOVID-19 nasal vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapeutics; Olorofim for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a COVID-19 prophylactic vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for COVID-19 treatment and prevention; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 for suppressing aggravation of COVID-19. In addition, the company develops S-540956 for nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer's disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for head and neck squamous cell carcinoma; S-005151 for Acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for cutaneous ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

Key Stats

• Today's Range: $6.87 to $7.14
• 50-Day Range: $6.59 to $7.36
• 52-Week Range: $6.22 to $9.11
• Volume: 268,719 shs
• Average Volume: 165,409 shs
• Market Capitalization: $11.69 billion
• P/E Ratio: 11.71
• Dividend Yield: 1.60%
• Price Target: N/A
• Consensus Rating: N/A

Shionogi & Co., Ltd. Stock Analysis - MarketRank™

Shionogi & Co., Ltd. scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Shionogi & Co., Ltd..

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -3.70%

Earnings Growth

Earnings for Shionogi & Co., Ltd. are expected to decrease by -3.70% in the coming year, from $0.27 to $0.26 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Shionogi & Co., Ltd. is 11.71, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 134.63.

Price to Earnings Ratio vs. Sector

The P/E ratio of Shionogi & Co., Ltd. is 11.71, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 133.56.

Price to Earnings Growth Ratio

Shionogi & Co., Ltd. has a PEG Ratio of 4.76. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Shionogi & Co., Ltd. has a P/B Ratio of 1.41. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.01% of the outstanding shares of Shionogi & Co., Ltd. have been sold short.

Short Interest Ratio / Days to Cover

Shionogi & Co., Ltd. has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Shionogi & Co., Ltd. has recently decreased by 45.89%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Shionogi & Co., Ltd. pays a meaningful dividend of 1.57%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Shionogi & Co., Ltd. does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Shionogi & Co., Ltd. is 18.64%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Shionogi & Co., Ltd. will have a dividend payout ratio of 42.31% next year. This indicates that Shionogi & Co., Ltd. will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.01% of the outstanding shares of Shionogi & Co., Ltd. have been sold short.

Short Interest Ratio / Days to Cover

Shionogi & Co., Ltd. has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Shionogi & Co., Ltd. has recently decreased by 45.89%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: N/A

News Sentiment

Shionogi & Co., Ltd. has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.

Search Interest

1 people have searched for SGIOY on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Shionogi & Co., Ltd. insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 1.92% of the stock of Shionogi & Co., Ltd. is held by institutions.

SGIOY Stock Analysis - Frequently Asked Questions

How have SGIOY shares performed this year?

Shionogi & Co., Ltd.'s stock was trading at $11.9720 on January 1st, 2024. Since then, SGIOY stock has decreased by 42.6% and is now trading at $6.87.
View the best growth stocks for 2024 here.

How were Shionogi & Co., Ltd.'s earnings last quarter?

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) released its earnings results on Wednesday, January, 31st. The company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by $0.11. The business earned $719.72 million during the quarter. Shionogi & Co., Ltd. had a trailing twelve-month return on equity of 11.95% and a net margin of 35.53%.

How do I buy shares of Shionogi & Co., Ltd.?

Shares of SGIOY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Company Calendar

• Last Earnings: 1/31/2024
• Today: 12/18/2024
• Fiscal Year End: 3/31/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Private households
• Sub-Industry: Personal Services
• Current Symbol: OTCMKTS:SGIOY
• CUSIP: N/A
• CIK: 1281721
• Web: www.shionogi.co.jp
• Phone: (166) 202-2161
• Fax: N/A
• Employees: 5,680
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): $0.59
• Trailing P/E Ratio: 11.80
• Forward P/E Ratio: 25.78
• P/E Growth: 4.76
• Net Income: $1.12 billion
• Net Margins: 35.53%
• Pretax Margin: 45.57%
• Return on Equity: 11.95%
• Return on Assets: 10.56%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 5.86
• Quick Ratio: 5.37

Sales & Book Value

• Annual Sales: $3.01 billion
• Price / Sales: 3.93
• Cash Flow: $0.69 per share
• Price / Cash Flow: 10.02
• Book Value: $4.86 per share
• Price / Book: 1.43

Miscellaneous

• Outstanding Shares: 1,701,379,000
• Free Float: N/A
• Market Cap: $11.84 billion
• Optionable: Not Optionable
• Beta: 0.21